Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,612 total articles
Picard Medical, Inc., parent company of SynCardia Systems, reported a 79.9% increase in revenue to $1.1 million for Q1 2026, driven by higher sales and utilization of its SynCardia Total Artificial Heart (STAH) and increased driver rental income. Favorable reimbursement and economic conditions in the U.S., alongside pricing adjustments in rental pr…
Stifel Financial Corp. announced record first quarter 2026 results, with net revenues of $1.48 billion, a 17.7% increase year-over-year, and net income available to common shareholders of $242.1 million, or $1.48 per diluted share, significantly higher than the prior year. Growth was driven by higher investment banking, asset management, and transa…
Rogers Communications delivered 10% year-over-year growth in total service revenue to $4.9 billion and 5% growth in adjusted EBITDA to $2.4 billion in Q1 2026. The company posted strong free cash flow growth of 32% to $776 million and improved its debt leverage ratio to 3.8x. Wireless and Cable segments showed EBITDA growth with subscriber addition…
Old National Bancorp reported strong Q1 2026 results including net income of $229.6 million and diluted EPS of $0.59, reflecting solid loan growth, improved capital ratios, and effective expense control. Key highlights include an 8.0% annualized loan growth, improved deposits, stable credit quality, and ongoing capital returns through share repurch…
Advantage Solutions Inc. announced that it will release its first quarter 2026 financial results on May 6, 2026, with a follow-up conference call to discuss the results. The company is a leading omnichannel retail solutions agency in North America serving CPG brands and retailers with data-driven services to optimize demand generation and product d…
Rogers Communications Inc. declared a quarterly dividend of 50 cents per share on both its Class A Voting shares and Class B Non-Voting shares, payable on July 6, 2026, to shareholders of record on June 9, 2026. The announcement underscores the company's commitment to returning value to investors.
SAB Biotherapeutics reported encouraging Phase 1 clinical trial results for SAB-142, its fully human anti-thymocyte globulin immunotherapy aimed at type 1 diabetes (T1D). The trial demonstrated C-peptide preservation and improved glycemic control in adult T1D participants, with most showing a 'super responder' profile linked to T cell exhaustion. T…
Aurora Mobile Limited (NASDAQ: JG) highlighted its AI-first customer engagement platform, EngageLab, at Japan's leading AI expo, NexTech Week Tokyo Spring 2026. The platform demonstrated integrated AI orchestration capabilities enabling autonomous execution of business processes across various communication channels, targeting key Japanese industri…
Ligand Pharmaceuticals, a Nasdaq-listed biopharmaceutical royalty aggregator, will release its first quarter 2026 financial results on May 7, 2026, followed by a conference call to discuss performance and provide a business update. The company manages a diverse portfolio of royalty interests and licenses proprietary drug development technologies.
BeyondSpring Inc. announced new preclinical data demonstrating that Plinabulin significantly improves both the anticancer efficacy and safety profile of leading antibody-drug conjugate (ADC) therapies. Presented at AACR 2026, the data show enhanced tumor response rates, longer survival, and reduced toxicities when Plinabulin is combined with ADCs w…
NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies, announced that four additional health insurers have adopted medical policy coverage for its IB-Stim Percutaneous Electrical Nerve Field Stimulation (PENFS) device. This expansion brings approximately 1.25 million more covered lives across several U.S. states, en…
Lantronix Inc., a Nasdaq-listed leader in Edge AI and Industrial IoT solutions, announced it will report its fiscal third quarter 2026 financial results on May 6, 2026, followed by a management-hosted conference call and webcast. The company provides intelligent computing and secure connectivity solutions for mission-critical applications across se…
Nutriband Inc.'s CEO Gareth Sheridan appeared on the Jack Neel Podcast to discuss the ongoing US fentanyl crisis and present Nutriband's AVERSA™ technology, which aims to improve safety by preventing abuse and misuse of transdermal drug patches like fentanyl. The technology is patent-protected internationally and the company is developing an abuse-…
Rafael Holdings, Inc. announced an exclusive licensing agreement with MIT for a patent covering cyclodextrin use in Alzheimer's patients carrying the ApoE4 gene variant. This expands the intellectual property portfolio for Trappsol® Cyclo™, which has shown promising preclinical effects on cholesterol transport, tau pathology reduction, and cognitiv…
Tenax Therapeutics, a Nasdaq-listed biotech company developing novel cardiopulmonary therapies, announced the appointment of Thomas R. Staab, II as Chief Financial Officer effective May 11, 2026. Mr. Staab brings over 25 years of healthcare and financial leadership experience, previously holding CFO roles at healthcare companies including BioCryst …
Certara, Inc. announced an agreement to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, aiming to sharpen focus and accelerate investments in its Model-Informed Drug Development (MIDD) and Clinical Intelligence platforms. The Regulatory and Medical Writing segment generated $50 million in revenue and $17 million…
Nurix Therapeutics announced encouraging preclinical results from multiple oncology programs at AACR 2026, demonstrating the potential of their targeted protein degradation pipeline. Key programs include the pan-mutant BRAF degrader NRX-0305, CBL-B intramolecular glue inhibitors (NX-1607), and Aurora Kinase A degrader NRX-4972. The data show enhanc…
Geron Corporation, a commercial-stage biopharmaceutical company focused on blood cancer treatments, announced it will release its Q1 2026 financial results and business highlights on May 6, 2026. The company will host a conference call and webcast to discuss these results. Geron is currently advancing its first-in-class telomerase inhibitor RYTELO®…
Ocular Therapeutix, a biopharmaceutical company specializing in retina disease treatments, announced an Investor Day event scheduled for June 17, 2026 in New York City with virtual access available. The event will feature senior leadership and key opinion leaders discussing its pipeline including the Phase 3 trials of AXPAXLI for wet AMD and diabet…
Eupraxia Pharmaceuticals announced it will present clinical data from its ongoing Phase 1b/2 RESOLVE trial of EP-104GI, an investigational long-acting corticosteroid for eosinophilic esophagitis, at the Digestive Disease Week 2026. The company will showcase multiple abstracts demonstrating persistent histological and clinical improvements. Addition…
Steven Madden, Ltd., a fashion-forward footwear and accessories company, announced it will release its first quarter 2026 earnings results on May 6, 2026, accompanied by a management conference call and webcast to discuss the financial performance.
KANZHUN LIMITED, also known as BOSS Zhipin, has announced that it has repurchased shares worth nearly RMB958 million so far in 2026, including RMB27.2 million spent on April 21 alone. This continued buyback activity highlights the company's commitment to enhancing shareholder value.
Amaze Holdings, Inc. has announced the launch of Amaze Live, a next-generation live shopping and community commerce platform enabling creators to sell live across social media, text, websites, and other owned channels. This platform is designed to expand the company's creator commerce ecosystem by providing real-time engagement and conversion oppor…
Taboola announced it will release its first quarter 2026 financial results on May 6, 2026, accompanied by a management conference call and webcast to discuss the earnings and company performance.
Amneal Pharmaceuticals announced its agreement to acquire Kashiv BioSciences, creating a fully integrated global biosimilars platform positioned to capitalize on a $300 billion global biologics loss-of-exclusivity opportunity. The transaction will accelerate Amneal's growth, diversify its portfolio, and enhance its biosimilar pipeline. Additionally…
